PharmiWeb.com - Global Pharma News & Resources
29-Feb-2024

Pediatric Clinical Trials Market Aims for Remarkable US$26.47 Billion Milestone by 2032

Future Market Insights projects that the paediatric clinical trials market sales will grow at a 5.3% annual pace between 2022 and 2032. From a projected US$ 15 billion in 2021 to a total valuation of US$ 26.47 billion by 2032, this market is anticipated to increase. The increase of chronic illnesses and genetic problems in children worldwide is anticipated to fuel market demand.

The Pediatric Clinical Trials Market is experiencing a noteworthy surge, driven by a heightened focus on advancing pediatric healthcare and ensuring the safety and efficacy of treatments for children. This specialized market plays a critical role in evaluating and developing medical interventions tailored specifically for pediatric populations. As awareness grows regarding the unique medical needs of children, stakeholders in the Pediatric Clinical Trials Market are actively collaborating to design and conduct trials that adhere to stringent ethical and regulatory standards. The market’s trajectory reflects an ongoing commitment to bridging knowledge gaps in pediatric medicine and improving the overall well-being of young patients through evidence-based research and development efforts.

The growing need for novel vaccines and biopharmaceuticals to treat infectious diseases such as measles, polio, tuberculosis, rubella, influenza, mumps, whooping cough, malaria, chickenpox, and staphylococcus pharyngitis is expected to drive market growth. At the same time, diabetes is a big worry among today’s children. The market is being driven by rising parental awareness of children clinical trials for severe infections and chronic diseases, as well as a large number of CROs doing pediatric research.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15017 

In 2021, the oncology therapeutic field category had the world’s second-largest revenue share. Cancer is the top cause of death in the globe. Cancer cases in children under the age of 19 are anticipated to reach 291,000 by 2040. With the increasing number of pediatric cancer cases worldwide, many hospitals and institutes are focusing on the development of therapeutic drugs, resulting in an increase in the number of pediatric clinical trials globally.

Irrespective of all these growth factors, the global market for pediatric clinical trials can be hindered for some specific reasons. The high rate of pediatric clinical trial discontinuation for a number of reasons is expected to impede growth in the pediatric clinical trials market. Pediatric studies have a high failure rate due to reasons such as patient enrollment. Other concerns include behavioral disorders and trial conduct issues such as inappropriate dosing, formulation difficulty, and informative termination, as well as regulatory challenges and pharmaceutical toxicity during clinical investigations.

Leading Companies Profiled in Pediatric Clinical Trials Market are

  • Synteract
  • ICON Plc.
  • Syneos Health
  • Medpace, Inc
  • PPD Inc.
  • Premier Research
  • LabCorp Drug Development
  • QPS Holding
  • Pfizer Inc.
  • The Emmes Company, LLC
  • IQVIA Inc.

Key Takeaways :

  • In 2022, the global pediatric clinical trials market is estimated to have a global market size of US$ 15.8 Billion
  • The pediatric clinical trials market in North America to acquire 45% of the global market share
  • APAC projected to acquire 25% of the global market share
  • By phase, the phase II clinical trials segment took over 33% of the global pediatric clinical trials market share
  • By study design, the treatment studies for clinical trials acquired 66% of the global market share
  • By therapeutic area, the oncology therapeutic area segment acquired almost 17% of the global market share

“The rising prevalence of chronic and hereditary diseases in children is driving this market to conduct more studies to improve treatment efficiency. Simultaneously, many clinical trials for COVID-19 vaccinations for children are being done, which is predicted to greatly increase market development. ” comments a Future Market Insights analyst.

Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-15017

Key Segments:

Pediatric Clinical Trials Market by Phase Type:

  • Phase I Pediatric Clinical Trials
  • Phase II Pediatric Clinical Trials
  • Phase III Pediatric Clinical Trials
  • Phase IV Pediatric Clinical Trials

Pediatric Clinical Trials Market by Study Design:

  • Treatment Studies of Pediatric Clinical Trials
  • Observational Studies of Pediatric Clinical Trials

Pediatric Clinical Trials Market by Therapeutic Areas:

  • Pediatric Clinical Trials for Infectious Diseases
  • Pediatric Clinical Trials for Oncology
  • Pediatric Clinical Trials for Autoimmune/Inflammatory Diseases
  • Pediatric Clinical Trials for Respiratory Disorders
  • Pediatric Clinical Trials for Mental Health Disorders
  • Pediatric Clinical Trials for Other Therapeutic Areas

Pediatric Clinical Trials Market by Region:

  • North American Pediatric Clinical Trials Market
  • Europe Pediatric Clinical Trials Market
  • Asia Pacific Pediatric Clinical Trials Market
  • Middle East & African Pediatric Clinical Trials Market
  • Latin America Pediatric Clinical Trials Market

Competitive Landscape

The industry analyzed is consolidated due to the sheer existence of a few key competitors in the market, with very few extra participants. Market participants’ key strategies included trial initialization, acquisitions, and collaborations.

  • In March 2022, Pfizer initiated a Phase 2/3 study for PAXLOVID tablets, which are specifically designed to treat COVID-19 in young patients. PAXLOVID reduced the risk of hospitalization or death from any cause by 89 percent (within three days of symptom onset) and 88 percent (within five days of appearance of symptoms).
  • In April 2021, Novartis announced plans to initiate SMART, a Phase 3b clinical trial to examine the safety and efficacy of Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global pediatric clinical trials market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of By Phase (Phase II, IV), By Study Design (Treatment, Observational Studies), By Therapeutic areas(Infectious Diseases, Oncology, Autoimmune/Inflammatory Diseases, Respiratory Disorders, Mental Health Disorders) and Region (North America, South America, Europe, Asia Pacific and Middle East & Africa).

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Editor Details

Last Updated: 29-Feb-2024